Literature DB >> 21204207

Genotype-phenotype analysis of the branchio-oculo-facial syndrome.

Jeff M Milunsky1, Tom M Maher, Geping Zhao, Zhenyuan Wang, John B Mulliken, David Chitayat, Michele Clemens, Heather J Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L Cunningham, Arlene V Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M Lachmeijer, Andre Megarbane, Nancy J Mendelsohn, Wendy S Meschino, Geert R Mortier, Sandhya Parkash, C Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L Whiteford, Derek A Wong, Roberto Zori, Angela E Lin.   

Abstract

Branchio-oculo-facial syndrome (BOFS; OMIM#113620) is a rare autosomal dominant craniofacial disorder with variable expression. Major features include cutaneous and ocular abnormalities, characteristic facies, renal, ectodermal, and temporal bone anomalies. Having determined that mutations involving TFAP2A result in BOFS, we studied a total of 30 families (41 affected individuals); 26/30 (87%) fulfilled our cardinal diagnostic criteria. The original family with the 3.2 Mb deletion including the TFAP2A gene remains the only BOFS family without the typical CL/P and the only family with a deletion. We have identified a hotspot region in the highly conserved exons 4 and 5 of TFAP2A that harbors missense mutations in 27/30 (90%) families. Several of these mutations are recurrent. Mosaicism was detected in one family. To date, genetic heterogeneity has not been observed. Although the cardinal criteria for BOFS have been based on the presence of each of the core defects, an affected family member or thymic remnant, we documented TFAP2A mutations in three (10%) probands in our series without a classic cervical cutaneous defect or ectopic thymus. Temporal bone anomalies were identified in 3/5 patients investigated. The occurrence of CL/P, premature graying, coloboma, heterochromia irides, and ectopic thymus, are evidence for BOFS as a neurocristopathy. Intrafamilial clinical variability can be marked. Although there does not appear to be mutation-specific genotype-phenotype correlations at this time, more patients need to be studied. Clinical testing for TFAP2A mutations is now available and will assist geneticists in confirming the typical cases or excluding the diagnosis in atypical cases.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21204207     DOI: 10.1002/ajmg.a.33783

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  19 in total

1.  Whole exome sequence analysis of Peters anomaly.

Authors:  Eric Weh; Linda M Reis; Hannah C Happ; Alex V Levin; Patricia G Wheeler; Karen L David; Erin Carney; Brad Angle; Natalie Hauser; Elena V Semina
Journal:  Hum Genet       Date:  2014-09-03       Impact factor: 4.132

2.  Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.

Authors:  Andrea R Hallberg; Sabine U Vorrink; Danielle R Hudachek; Kimberly Cramer-Morales; Mohammed M Milhem; Robert A Cornell; Frederick E Domann
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

3.  The atypical mitogen-activated protein kinase ERK3 is essential for establishment of epithelial architecture.

Authors:  Chika Takahashi; Koichi Miyatake; Morioh Kusakabe; Eisuke Nishida
Journal:  J Biol Chem       Date:  2018-04-19       Impact factor: 5.157

4.  Overlapping expression patterns and redundant roles for AP-2 transcription factors in the developing mammalian retina.

Authors:  Erin A Bassett; Anna Korol; Paula A Deschamps; Reinhard Buettner; Valerie A Wallace; Trevor Williams; Judith A West-Mays
Journal:  Dev Dyn       Date:  2012-04       Impact factor: 3.780

Review 5.  Neural crest contributions to the ear: Implications for congenital hearing disorders.

Authors:  K Elaine Ritter; Donna M Martin
Journal:  Hear Res       Date:  2018-11-14       Impact factor: 3.208

Review 6.  Modeling craniofacial and skeletal congenital birth defects to advance therapies.

Authors:  Cynthia L Neben; Ryan R Roberts; Katrina M Dipple; Amy E Merrill; Ophir D Klein
Journal:  Hum Mol Genet       Date:  2016-06-26       Impact factor: 6.150

7.  Analysis of TFAP2A mutations in Branchio-Oculo-Facial Syndrome indicates functional complexity within the AP-2α DNA-binding domain.

Authors:  Hong Li; Ryan Sheridan; Trevor Williams
Journal:  Hum Mol Genet       Date:  2013-04-10       Impact factor: 6.150

8.  Tfap2a and 2b act downstream of Ptf1a to promote amacrine cell differentiation during retinogenesis.

Authors:  Kangxin Jin; Haisong Jiang; Dongchang Xiao; Min Zou; Jun Zhu; Mengqing Xiang
Journal:  Mol Brain       Date:  2015-05-13       Impact factor: 4.041

9.  Tfap2a-dependent changes in mouse facial morphology result in clefting that can be ameliorated by a reduction in Fgf8 gene dosage.

Authors:  Rebecca M Green; Weiguo Feng; Tzulip Phang; Jennifer L Fish; Hong Li; Richard A Spritz; Ralph S Marcucio; Joan Hooper; Heather Jamniczky; Benedikt Hallgrímsson; Trevor Williams
Journal:  Dis Model Mech       Date:  2014-11-07       Impact factor: 5.758

10.  The AP-2 Transcription Factor APTF-2 Is Required for Neuroblast and Epidermal Morphogenesis in Caenorhabditis elegans Embryogenesis.

Authors:  Yemima Budirahardja; Pei Yi Tan; Thang Doan; Peter Weisdepp; Ronen Zaidel-Bar
Journal:  PLoS Genet       Date:  2016-05-13       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.